STOCK TITAN

Windward Bio to Participate at the Jefferies London Global Healthcare Conference

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Windward Bio (Nasdaq: WWB) management will present at the Jefferies London Global Healthcare Conference on November 18, 2026, at 8:30 a.m. GMT.

A live and archived webcast of the fireside chat will be available through the News & Events page in the Investors section of the company website.

Loading...
Loading translation...

Key Terms

copd, monoclonal antibody, tslp, bispecific antibody, +1 more
5 terms
copd medical
"chronic obstructive pulmonary disease (COPD)"
Chronic obstructive pulmonary disease (COPD) is a long-term lung condition that progressively narrows airways and reduces the ability to breathe, causing persistent cough, shortness of breath and fatigue. It matters to investors because a large and growing patient population creates steady demand for drugs, medical devices and care services, influences healthcare spending and regulatory decisions, and offers clear market opportunities—similar to a leaking engine that requires ongoing fixes and replacement parts.
monoclonal antibody medical
"a fully human monoclonal antibody designed to inhibit thymic stromal lymphopoietin"
A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.
tslp medical
"thymic stromal lymphopoietin (TSLP)"
TSLP (thymic stromal lymphopoietin) is an immune-system signaling protein that acts like an alarm, triggering inflammation in conditions such as asthma and allergic disease. Investors watch TSLP because drugs that block its action can reduce symptoms and prevent flares; successful clinical trials or approvals for TSLP-targeting therapies can materially change a biotech company's prospects, market value, and potential market size for respiratory and allergic treatments.
bispecific antibody medical
"an ultra-long-acting bispecific antibody targeting TSLP and interleukin-13"
A bispecific antibody is a specially designed protein that can attach to two different targets at the same time. Think of it as a custom-made connector that brings two things together—such as a disease cell and an immune system component—helping the body fight illnesses more effectively. For investors, understanding bispecific antibodies is important because they represent innovative therapies that could lead to new treatments and potentially lucrative market opportunities.
il-13 medical
"interleukin-13 (IL-13)"
IL-13 is a small signaling protein produced by the immune system that plays a key role in allergic inflammation and certain lung and fibrotic diseases; think of it as a radio message that tells cells to make mucus, narrow airways, or lay down scar tissue. For investors, IL-13 matters because therapies that block or measure it can change patient outcomes and determine the success of clinical trials, regulatory approvals, and the value of companies developing targeted drugs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

BASEL, Switzerland, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Windward Bio Group AG ("Windward") (Nasdaq: WWB), a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, today announced that members of management will present at the Jefferies London Global Healthcare Conference on Wednesday, November 18, 2026, at 8:30 a.m.GMT.

A live and archived webcast of the fireside chat will be available via the News & Events page in the Investors section of the Windward Bio website.

About Windward Bio Group AG

Windward (Nasdaq: WWB) is a global, clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis. Its lead product candidate, WIN378, is a fully human monoclonal antibody designed to inhibit thymic stromal lymphopoietin (TSLP) and is being evaluated in the POLARIS-1 Phase 2/3 study in severe uncontrolled asthma and the SIRIUS Phase 2 study in COPD. Windward’s second product candidate, WIN027, is an ultra-long-acting bispecific antibody targeting TSLP and interleukin-13 (IL-13) and is currently in a Phase 1 healthy volunteer study.

For media and investor inquiries:
Noel Kurdi
SVP, Investor Relations and Communications
Windward Bio
investors@windwardbio.com


Keep reading